ERLEADA 60 MG
APALUTAMIDE : 60 MG · DIN 02478374 · JANSSEN INC
Health Canada status: MARKETED
What is ERLEADA?
ERLEADA 60 MG contains APALUTAMIDE : 60 MG. It is listed in the Health Canada Drug Product Database under DIN 02478374, held by JANSSEN INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ERLEADA used for?
ERLEADA® (apalutamide tablets) is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) and for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). ERLEADA® has not been studied in patients with nmCRPC at low risk of developing metastases.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02478374 |
|---|---|
| Brand name | ERLEADA |
| Generic / active ingredient | APALUTAMIDE : 60 MG |
| Manufacturer | JANSSEN INC |
| Strength | 60 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L02BB05 APALUTAMIDE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-Jul-2018 |
| Original market date | 2018-07-27 00:00:00 |
How is it supplied?
60 mg tablets are supplied in bottles of 120 tablets. 240 mg tablets are supplied in bottles of 30 tablets.
What can be used instead?
Other Canadian products sharing ATC code L02BB05 APALUTAMIDE. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ERLEADA | 240 MG | TABLET | JANSSEN INC | MARKETED | DIN 02540185 |
Who else supplies APALUTAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. APALUTAMIDE appears in 25 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.